Safety,
Tolerability, and
Outcomes of Velpatasvir/Sofosbuvi
R in Treatment of Chronic Hepatitis
C Virus during Pregnancy (STORC)
1. To evaluate the sustained virologic response 12 weeks after completion of SOF/VEL treatment (SVR12) in women treated during pregnancy.
2. To evaluate impact of antenatal treatment with SOF/VEL on the gestational age at delivery for women who received SOF/VEL for HCV treatment during pregnancy.
Primary Investigator: John Cafardi